Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
B Shariat-Madar1, D Kolte2, A Verlangieri2, Z Shariat-Madar21College of Literature, Science, and the Arts, University of Michigan, Ann Arbor MI, USA; 2School of Pharmacy, Department of Pharmacology, University of Mississippi, University, MS, USAAbstract: Recently, we serendipitously discovered that...
Guardado en:
Autores principales: | Shariat-Madar Z, Shariat-Madar B, Kolte D, Verlangieri AJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9b938dab003c40599c17b59fc30f487c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
por: B Shariat-Madar, et al.
Publicado: (2010) -
Influence of FTO rs9939609 polymorphism on appetite, ghrelin, leptin, IL6, TNFα levels, and food intake of women with morbid obesity
por: Magno FCCM, et al.
Publicado: (2018) -
The Association Between Serum Thyrotropin Within the Reference Range and Metabolic Syndrome in a Community-Based Chinese Population
por: Li M, et al.
Publicado: (2020) -
Evaluation of single nucleotide polymorphisms of Pro12Ala in peroxisome proliferator-activated receptor-γ and Gly308Ala in tumor necrosis factor-α genes in obese Asian Indians: a population-based study
por: Gupta R
Publicado: (2010) -
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publicado: (2009)